Baseline patient demographic and disease characteristics
| Characteristic . | Imatinib resistant (n = 200) . | Imatinib intolerant (n = 88) . | Total (N = 288) . | |||
|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | |
| Age, y | ||||||
| Median | 51.0 | 54.5 | 53.0 | |||
| Range | 18-86 | 23-91 | 18-91 | |||
| Sex, male | 116 | 58 | 38 | 43 | 154 | 53 |
| Hematologic analysis, 109/L | ||||||
| White blood cell count | ||||||
| Median | 6.7 | 5.9 | 6.5 | |||
| Range | 2.1-151 | 2.1-160.7 | 2.1-151 | |||
| Platelet count | ||||||
| Median | 261.5 | 202.5 | 237.5 | |||
| Range | 47-2436 | 48-2251 | 47-2436 | |||
| Duration of disease, y | ||||||
| Median | 4.0 | 2.8 | 3.6 | |||
| Range | 0.1-15.1 | 0.1-13.6 | 0.1-15.1 | |||
| Treatment history | ||||||
| No. of previous therapies* | ||||||
| 1 | 131 | 66 | 65 | 74 | 196 | 68 |
| 2 | 69 | 35 | 23 | 26 | 92 | 32 |
| Previous IFN | 69 | 35 | 23 | 26 | 92 | 32 |
| Previous stem cell transplantation | 6 | 3 | 2 | 2 | 8 | 3 |
| Features of imatinib treatment | ||||||
| Duration of previous imatinib treatment, y | ||||||
| Median | 2.6 | 1.5 | 2.2 | |||
| Range | 0.4-8.8 | < 0.1-8.3 | < 0.1-8.8 | |||
| Previous complete hematologic response with imatinib | 164 | 82 | 55 | 63 | 219 | 76 |
| Reason for stopping imatinib | ||||||
| Adverse event (intolerance)† | 1 | 1 | 86 | 98 | 87 | 33 |
| Disease progression | 163 | 92 | 1 | 1 | 164 | 62 |
| Regimen completed | 7 | 4 | 0 | 0 | 8 | 3 |
| Other | 7 | 4 | 1 | 1 | 7 | 3 |
| Missing‡ | 22 | 0 | 22 | |||
| 1 or more Bcr-Abl mutations detected§ | 57/83 | 69 | 8/32 | 25 | 65/115 | 57 |
| Characteristic . | Imatinib resistant (n = 200) . | Imatinib intolerant (n = 88) . | Total (N = 288) . | |||
|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | |
| Age, y | ||||||
| Median | 51.0 | 54.5 | 53.0 | |||
| Range | 18-86 | 23-91 | 18-91 | |||
| Sex, male | 116 | 58 | 38 | 43 | 154 | 53 |
| Hematologic analysis, 109/L | ||||||
| White blood cell count | ||||||
| Median | 6.7 | 5.9 | 6.5 | |||
| Range | 2.1-151 | 2.1-160.7 | 2.1-151 | |||
| Platelet count | ||||||
| Median | 261.5 | 202.5 | 237.5 | |||
| Range | 47-2436 | 48-2251 | 47-2436 | |||
| Duration of disease, y | ||||||
| Median | 4.0 | 2.8 | 3.6 | |||
| Range | 0.1-15.1 | 0.1-13.6 | 0.1-15.1 | |||
| Treatment history | ||||||
| No. of previous therapies* | ||||||
| 1 | 131 | 66 | 65 | 74 | 196 | 68 |
| 2 | 69 | 35 | 23 | 26 | 92 | 32 |
| Previous IFN | 69 | 35 | 23 | 26 | 92 | 32 |
| Previous stem cell transplantation | 6 | 3 | 2 | 2 | 8 | 3 |
| Features of imatinib treatment | ||||||
| Duration of previous imatinib treatment, y | ||||||
| Median | 2.6 | 1.5 | 2.2 | |||
| Range | 0.4-8.8 | < 0.1-8.3 | < 0.1-8.8 | |||
| Previous complete hematologic response with imatinib | 164 | 82 | 55 | 63 | 219 | 76 |
| Reason for stopping imatinib | ||||||
| Adverse event (intolerance)† | 1 | 1 | 86 | 98 | 87 | 33 |
| Disease progression | 163 | 92 | 1 | 1 | 164 | 62 |
| Regimen completed | 7 | 4 | 0 | 0 | 8 | 3 |
| Other | 7 | 4 | 1 | 1 | 7 | 3 |
| Missing‡ | 22 | 0 | 22 | |||
| 1 or more Bcr-Abl mutations detected§ | 57/83 | 69 | 8/32 | 25 | 65/115 | 57 |
Includes previous tyrosine kinase inhibitor therapies. Percentages may not total 100% because of rounding.
Patients simultaneously meeting the protocol definitions for imatinib resistance and imatinib intolerance are categorized as having imatinib resistance.
The reason for stopping imatinib was not reported.
Total of 83 imatinib-resistant and 32 imatinib-intolerant patients assessed for mutation status at baseline.